How much does pegloticase cost?
Pegloticase (traditionally marketed for gout as Krystexxa) is priced as an infused specialty medicine, so the real “out-of-pocket” cost usually depends on insurance coverage, prior authorization, and patient-specific factors. The total billed cost can also vary by infusion setting and location.
What drives the price you’ll actually pay (insurance vs cash price)?
The cash price for pegloticase is typically much higher than the amount paid with insurance. Your final cost depends on:
- Your insurance type and formulary status (specialty drug tier)
- Prior authorization approval and treatment criteria
- Whether you receive infusions in a hospital outpatient department, infusion center, or clinic
- Your deductible, coinsurance, and copay/maximum out-of-pocket for the year
Are there patient assistance or copay programs?
Many specialty drugs offer one or more of the following to help reduce costs:
- Manufacturer patient assistance programs for eligible uninsured/low-income patients
- Copay cards (for commercially insured patients, when available)
- Financial assistance programs that reduce copays or coinsurance
Eligibility rules and availability can change, so the best next step is checking the current program terms for the specific product name and your insurance status.
How long treatment lasts and what that means for total cost
Pegloticase is given by infusion on a dosing schedule over multiple sessions. That means total therapy cost is driven by the number of infusions in the planned course, not a single dose. Your clinician can estimate how many infusions are likely to be required for your situation.
What side effects risks might affect coverage or treatment decisions?
Coverage decisions and clinical use often reflect safety and monitoring requirements. Pegloticase carries risks that can lead to additional monitoring costs (for example, infusion reactions and the need for appropriate premedication protocols).
If pegloticase is too expensive, what alternatives are commonly considered?
Patients and clinicians often compare pegloticase costs and risks against other gout urate-lowering strategies (including other urate-lowering therapies) based on:
- Whether you have refractory chronic gout
- Kidney function considerations
- Prior response to other treatments
- Insurance coverage and out-of-pocket affordability
If you tell me your country (and whether you have Medicare, Medicaid, or commercial insurance) I can help narrow what cost ranges or assistance options usually apply and what to check next.